Glenmark Pharmaceuticals Inc., USA has announced the launch of Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial dosages. This new product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA, LLC.
The market for Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, achieved annual sales of approximately $37.9 million for the 12-month period ending March 2026, according to IQVIA® sales data. This includes both branded and all available therapeutic equivalents.
Marc Kikuchi, President & Business Head for North America, commented on the launch, stating that it reflects Glenmark’s ongoing commitment to providing quality, affordable medicines in the U.S. It also enhances the company’s injectable portfolio and supports its focus on delivering reliable treatment options to healthcare providers and patients.
Glenmark’s Vancomycin Hydrochloride for Injection USP is approved only for the indications listed in the company’s approved label and is not marketed for all reference listed drug (RLD) indications.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).